These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29209907)

  • 1. Scientific white paper on concentration-QTc modeling.
    Garnett C; Bonate PL; Dang Q; Ferber G; Huang D; Liu J; Mehrotra D; Riley S; Sager P; Tornoe C; Wang Y
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):383-397. PubMed ID: 29209907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates.
    Gaitonde P; Huh Y; Darpo B; Ferber G; Heimann G; Li J; Lu K; Sebastien B; Tsai K; Riley S
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):617-626. PubMed ID: 31667657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure-response analysis.
    Tsamandouras N; Duvvuri S; Riley S
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):605-616. PubMed ID: 31664592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
    Rossman EI; Wisialowski TA; Vargas HM; Valentin JP; Rolf MG; Roche BM; Riley S; Pugsley MK; Nichols J; Li D; Leishman DJ; Kleiman RB; Greiter-Wilke A; Gintant GA; Engwall MJ; Delaunois A; Authier S
    J Pharmacol Toxicol Methods; 2023; 123():107270. PubMed ID: 37164235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods.
    Lu J; Li J; Helmlinger G; Al-Huniti N
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):469-482. PubMed ID: 29556866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
    Rohatagi S; Carrothers TJ; Kuwabara-Wagg J; Khariton T
    J Clin Pharmacol; 2009 Nov; 49(11):1284-96. PubMed ID: 19734373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enabling robust assessment of QTc prolongation in early phase clinical trials.
    Mehrotra DV; Fan L; Liu F; Tsai K
    Pharm Stat; 2017 May; 16(3):218-227. PubMed ID: 28374497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Operational Characteristics of Linear Concentration-QT Models for Assessing QTc Interval in the Thorough QT and Phase I Clinical Studies.
    Garnett C; Needleman K; Liu J; Brundage R; Wang Y
    Clin Pharmacol Ther; 2016 Aug; 100(2):170-8. PubMed ID: 26946218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of dependent variable, time effect, covariates, and covariation structure in concentration-QTc modeling: A simulation study.
    Huang DP; Xiao S; Dang Q; Tsong Y
    Pharm Stat; 2018 Sep; 17(5):607-614. PubMed ID: 29956449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes.
    Malik M; Garnett C; Hnatkova K; Johannesen L; Vicente J; Stockbridge N
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):491-503. PubMed ID: 29651591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.
    Cavero I; Holzgrefe H; Clements M
    J Pharmacol Toxicol Methods; 2016; 80():1-8. PubMed ID: 26903171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug response hysteresis in the concentration-QTc analysis of early clinical trials.
    Li H; Tong B; Hosmane B; Chiu YL
    J Biopharm Stat; 2021 Sep; 31(5):705-722. PubMed ID: 34224329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies.
    Darpo B; Borin M; Ferber G; Galluppi GR; Hopkins SC; Landry I; Lo A; Rege B; Reyderman L; Sun L; Watanabe T; Xue H; Yasuda S
    J Clin Pharmacol; 2022 Dec; 62(12):1480-1500. PubMed ID: 35665514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.
    Darpo B
    Br J Pharmacol; 2010 Jan; 159(1):49-57. PubMed ID: 19922536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-physiology interaction and its influence on the QT prolongation-mechanistic modeling study.
    Wiśniowska B; Polak S
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):483-490. PubMed ID: 29546612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?".
    Darpo B; Sarapa N; Garnett C; Benson C; Dota C; Ferber G; Jarugula V; Johannesen L; Keirns J; Krudys K; Ortemann-Renon C; Riley S; Rogers-Subramaniam D; Stockbridge N
    Ann Noninvasive Electrocardiol; 2014 Jan; 19(1):70-81. PubMed ID: 24372708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Studies Evaluating QT/QTc Interval Prolongation with Dietary Supplements Meet FDA Standards: A Systematic Review.
    Nguyen TA; Kurian A; Leong J; Patel UM; Shah SA
    J Diet Suppl; 2017 Jul; 14(4):467-477. PubMed ID: 27937000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011-2019.
    Cohen-Rabbie S; Berges AC; Rekić D; Parkinson J; Dota C; Tomkinson HK
    J Clin Pharmacol; 2021 Aug; 61(8):1106-1117. PubMed ID: 33624833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.